Prometheus Biosciences to Participate at the Jefferies Healthcare Conference

Rhea-AI Summary

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology firm, will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:00 AM ET. The company focuses on precision medicine for immune-mediated diseases and utilizes its Prometheus360™ platform to identify therapeutic targets. Its lead candidate, PRA023, is an IgG1 humanized monoclonal antibody aimed at treating conditions like Ulcerative Colitis, Crohn's Disease, and systemic sclerosis-associated interstitial lung disease. Live and archived webcasts of the presentation will be available on their website.

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will present at the Jefferies Healthcare Conference on June 8, 2022 at 10:00 AM ET.

A live and archived webcast of the presentation will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360^TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of immune-mediated diseases including Ulcerative colitis (UC), Crohn’s disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The Company is currently conducting three Phase 2 studies of PRA023: a Phase 2 trial in UC patients, ARTEMIS-UC, a Phase 2a trial in CD patients, APOLLO-CD, and a Phase 2 clinical trial in SSc-ILD, ATHENA-SSc-ILD, each utilizing a genetic-based companion diagnostic candidate designed to classify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023.

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com 

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com 

FAQ

When will Prometheus Biosciences present at the Jefferies Healthcare Conference?

Prometheus Biosciences will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:00 AM ET.

What is the focus of Prometheus Biosciences?

Prometheus Biosciences focuses on precision medicine for the treatment of immune-mediated diseases.

What is Prometheus Biosciences' lead candidate?

The lead candidate of Prometheus Biosciences is PRA023, an IgG1 humanized monoclonal antibody for immune-mediated diseases.

What diseases is PRA023 targeted to treat?

PRA023 is targeted to treat Ulcerative Colitis, Crohn's Disease, and systemic sclerosis-associated interstitial lung disease.

Where can I find the webcast of the presentation?

The live and archived webcast of the presentation will be available on the Events & Webcasts page of the Prometheus Biosciences website.